Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Earnings
Intra-Cellular Therapies beat estimated earnings by 15.22%, reporting an EPS of $-0.78 versus an estimate of $-0.92.
Revenue was up $19.12 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.05 which was followed by a 0.97% increase in the share price the next day.
Here's a look at Intra-Cellular Therapies's past performance:
| Quarter | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|
| EPS Estimate | -1 | -0.92 | -0.80 | -0.80 |
| EPS Actual | -1.05 | -0.95 | -0.85 | -0.65 |
| Revenue Estimate | 25.37M | 22.12M | 19.44M | 16.50M |
| Revenue Actual | 25.67M | 22.21M | 20.05M | 15.88M |
To track all earnings releases for Intra-Cellular Therapies visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
